S Legha
Overview
Explore the profile of S Legha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castro M, VanAuken J, Legha S, Sponzo R
Cancer
. 1999 Mar;
85(5):1055-9.
PMID: 10091788
Background: Treatment of solid tumors rarely has been associated with tumor lysis syndrome. However, to the authors' knowledge the clinical scenario has not been reported previously in melanoma patients. Methods:...
2.
Raad I, Hachem R, Abi-Said D, Rolston K, Whimbey E, Buzaid A, et al.
Cancer
. 1998 Jan;
82(2):403-11.
PMID: 9445199
Background: The aim of this study was to determine the efficacy of novobiocin and rifampin as oral antibiotic prophylaxis for the prevention of catheter-related infection in melanoma patients treated with...
3.
Murray J, Kleinerman E, Jia S, Rosenblum M, Eton O, Buzaid A, et al.
J Immunother Emphasis Tumor Immunol
. 1996 May;
19(3):206-17.
PMID: 8811495
We performed a phase Ia/Ib trial of chimeric anti-GD2 monoclonal antibody 14.18 (ch14.18) in combination with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to determine the maximum tolerated dose as well...
4.
Parkinson D, Talpaz M, Lee K, Legha S, Markowitz A, Itoh K, et al.
Cancer Treat Rev
. 1989 Jun;
16 Suppl A:39-48.
PMID: 2670214
The clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently,...
5.
Raber M, Newman R, Lu K, Legha S, Gorski C, Benjamin R, et al.
Cancer Chemother Pharmacol
. 1989 Jan;
23(5):311-5.
PMID: 2706737
Tetrahydropyranyladriamycin (THP-adriamycin) is an anthracycline analogue currently under development in Europe and Japan. Preclinical studies suggest that it may have greater activity and less cardiac toxicity than doxorubicin. We conducted...
6.
Raber M, Adams F, Kavanagh J, Legha S, Dimery I, KRAKOFF I
Cancer Treat Rep
. 1987 Apr;
71(4):349-52.
PMID: 3548956
We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon) human tumor xenografts. Using a 5-day bolus schedule,...
7.
Inamasu M, Oishi N, Chen T, Legha S, McCracken J, Balcerzak S, et al.
Cancer Treat Rep
. 1984 Nov;
68(11):1411-2.
PMID: 6548661
No abstract available.
8.
Dixon C, Hagemeister F, Legha S, Bodey G
Cancer Treat Rep
. 1984 Jun;
68(6):907-8.
PMID: 6733705
No abstract available.
9.
Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G
Cancer Treat Rep
. 1983 Jun;
67(6):599-600.
PMID: 6344995
No abstract available.
10.
Bukowski R, Legha S, Saiki J, Eyre H, OBryan R
Cancer Treat Rep
. 1982 Aug;
66(8):1651-2.
PMID: 6286120
Twenty-three patients with heptocellular carcinoma were treated with m-AMSA at a dose of 120 mg/m2 iv repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in two of...